Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Table 12 Biochemical parameters data of non-acute and acute decompensating patients

Variables (mean ± SD)	NAD-decompensating patients (n = 29)	AD-decompensating patients (n =14)	P value1
AST (IU/L)	27.93 ± 26.99	44.11 ± 11.26	0.004
ALT (IU/L)	40.10 ± 35.52	54.71 ± 51.23	NS
Bilirubin (µmol/L)	21.75 ± 5.32	26.94 ± 1.32	NS
PLT count (mm3)	100.2 ± 24.37	61.57 ± 14.12	< 0.0001
RDW-CV (%)	26.16 ± 19.26	51.51 ± 21.23	< 0.0001
RDW-SD (fL)	54.39 ± 10.21	64.10 ± 10.14	< 0.0001
Albumin (g/L)	28.6 ± 2.21	21.8 ± 2.59	NS
INR	1.76 ± 0.66	1.96 ± 0.62	NS
HOMA-IR	3.44 ± 1.29	4.12 ± 1.09	NS
Total cholesterol (mg/dL)	195.4 ± 56.20	164.4 ± 44.17	NS
Tryglicerides (mg/dL)	167.4 ± 92.42	152.1 ± 60.71	NS
Creatinine (mg/dL)	1.27 ± 1.51	2.61 ± 1.22	0.03

¹Mann-Whitney U test.

Statistically significant differences (P < 0.05) are reported in bold. ALT: Alanine aminotransferase; PLT: Platelets count; CV: Coefficient variation; RDW: Red-cell distribution width; INR: International normalized ratio; HOMA-IR: homeostasis model assessment for insulin resistance; NS: Not statistically significant; AD: Acute decompensation; NAD: Non-acute decompensation.